BIO Form 4: Rajat Mehta Receives 7,307 RSUs with Four-Year Vesting
Rhea-AI Filing Summary
Rajat Mehta, Executive Vice President, Global Commercial Operations at Bio-Rad Laboratories, Inc. (BIO), reported grants of restricted stock units on 09/05/2025. The Form 4 shows two awards: 1,827 RSUs and 5,480 RSUs, each representing the contingent right to one share of Bio-Rad Class A common stock. Both grants have a $0 per-unit reported conversion price and are held directly by the reporting person. The 1,827 RSUs vest in four equal annual installments beginning on the first anniversary of the grant date; the 5,480 RSUs vest over four years at 25% per year on each annual anniversary. The filing is signed 09/09/2025.
Positive
- Long-term alignment: Grants vest over four years, encouraging retention and alignment with shareholder interests
- Direct ownership: RSUs are held directly by the reporting person, making the executive a reported beneficial owner
Negative
- Potential dilution: 7,307 RSUs will convert into shares upon settlement, increasing outstanding shares
- No disclosed performance conditions: Awards appear to be time-based only, not explicitly tied to measurable performance targets
Insights
TL;DR: Standard executive equity grants with multi-year vesting; aligns executive incentives with shareholder interests but dilutive over time.
The filing documents time-based restricted stock unit awards to a senior executive, which is a common long-term incentive. The awards vest over four years at 25% annually, encouraging retention and alignment with company performance. The grants are reported as direct holdings and have a $0 conversion price because RSUs convert into shares rather than being purchased. From a governance perspective, the structure is routine; materiality depends on the executive's overall holdings and total outstanding shares, which are not disclosed in this form.
TL;DR: Time-based RSU grants consistent with market practice; non-performance-based awards provide retention but lack explicit performance linkage.
The awards total 7,307 RSUs and vest 25% per year over four years. As RSUs, they deliver value only if the recipient remains employed and, upon settlement, dilute existing shareholders. The Form 4 does not show performance conditions or service-only exceptions beyond the stated vesting schedule. Without additional context on target pay levels or total dilution, this appears to be a routine retention award rather than a performance-contingent incentive.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Units | 1,827 | $0.00 | -- |
| Grant/Award | Restricted Stock Units | 5,480 | $0.00 | -- |
Footnotes (1)
- Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. On September 5, 2025, the reporting person was granted 1,827 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.
